Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …

Mesenchymal stem/stromal cells (MSCs) are a promising resource for cell-based therapy
because of their high immunomodulation ability, tropism towards inflamed and injured …

Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and
metastasis through various mechanisms and is now recognized as a hallmark of cancer and …

The anti-tumor activities of some members of the chemokine family are often overcome by
the functions of many chemokines that are strongly and causatively linked with increased …

Tumor heterogeneity is a hallmark of cancer and one of the primary causes of resistance to
therapies. Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast …

Background Combination of chemotherapy and immune checkpoint inhibitor therapy has
greatly improved the anticancer effect on multiple malignancies. However, the efficiency on …

Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by poor
response to standard therapies and therefore unfavorable clinical outcomes. Better …

About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do
not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment …

Breast cancer is the most prevalent cancer worldwide, and metastasis is the leading cause
of death in cancer patients. Human monocyte chemoattractant protein-1 (MCP-1/CCL2) was …

Background Breast cancer (BC), one of the most prevalent malignancies, is the second
major cause of mortality from cancer among women worldwide. Even though substantial …